Andrew J.S. Furness

Employment

• Royal Marsden NHS Foundation Trust Consultant Medical Oncologist And Cellular Therapist
  2019 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (177)

• Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme.
  Oncologist 2026 DOI: 10.1093/oncolo/oyag341
  +Save
• ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.
  Annals of Surgical Oncology 2026 DOI: 10.1245/s10434-026-19486-4
  +Save
• The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.
  Annals of Surgical Oncology 2026 DOI: 10.1245/s10434-026-19340-7
  +Save
• Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
  Journal for ImmunoTherapy of Cancer 2026 DOI: 10.1136/jitc-2026-015360
  +Save
• Figure 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.28523051
  +Save
• Figure 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.28523048
  +Save
• Supplementary Figures 1-33 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701141
  +Save
• Supplementary Note 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701138
  +Save
• Supplementary Note 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701135
  +Save
• Supplementary Table 1 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701129
  +Save
• Supplementary Table 10 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701126
  +Save
• Supplementary Table 11 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701123
  +Save
• Supplementary Table 2 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701117
  +Save
• Supplementary Table 3 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701108
  +Save
• Supplementary Table 4 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701102
  +Save
• Supplementary Table 5 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701096
  +Save
• Supplementary Table 6 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701087
  +Save
• Supplementary Table 7 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701081
  +Save
• Supplementary Table 8 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701075
  +Save
• Supplementary Table 9 from Tracking Nongenetic Evolution from Primary to Metastatic ccRCC: TRACERx Renal
  2026 DOI: 10.1158/2159-8290.32701072
  +Save